When the patent of an originator drug (i.e. the original protected drug) expires, the manufacturer of that drug may be tempted, while waiting for the protection of new processes by new patents, to prevent the arrival of generics into the market. Under the guise of settling patent disputes, “pay for delay” agreements are reached with